Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Suppressing commercial speech is not in the best interests of physicians and patients.

Chressanthis G, Khedkar P, Jain N, Poddar P, Seiders M.

J Clin Hypertens (Greenwich). 2013 Mar;15(3):219-20. doi: 10.1111/jch.12043. Epub 2012 Dec 10. No abstract available.

2.

Should physicians rely on pharmaceutical detailing for their education?

van Schalkwyk JM, Turner MJ.

J Clin Hypertens (Greenwich). 2013 Mar;15(3):218. doi: 10.1111/jch.12044. Epub 2012 Dec 14. No abstract available.

3.

The details are in the field.

Schwab AP.

Am J Bioeth. 2010 Jan;10(1):19-21. doi: 10.1080/15265160903460921. No abstract available.

PMID:
20077330
4.

[Strategies for drug promotion].

Polonuer JL.

Medicina (B Aires). 2005;65(4):373-6. Spanish. No abstract available.

PMID:
16193722
5.

Avoiding over-deterrence in managing physicians' relationships with industry.

Stell LK.

Am J Bioeth. 2010 Jan;10(1):27-9. doi: 10.1080/15265160903441129. No abstract available.

PMID:
20077334
6.

The devil in the detail(ing).

Morreim H.

Am J Bioeth. 2010 Jan;10(1):15-7. doi: 10.1080/15265160903460905. No abstract available.

PMID:
20077328
7.

Drug detailers, professionalism, and prudence.

Brody H.

Am J Bioeth. 2010 Jan;10(1):9-10. doi: 10.1080/15265160903441020. No abstract available.

PMID:
20077325
8.

Huddle gets it right, most docs don't.

Rubin PH.

Am J Bioeth. 2010 Jan;10(1):17-9. doi: 10.1080/15265160903441087. No abstract available.

PMID:
20077329
9.

Contact with pharmaceutical representatives: where does prudence lead?

Appelbaum PS.

Am J Bioeth. 2010 Jan;10(1):11-3. doi: 10.1080/15265160903441046. No abstract available.

PMID:
20077326
10.

Why academic medical centers should ban drug company gifts to individuals.

Strong C.

Am J Bioeth. 2010 Jan;10(1):13-5. doi: 10.1080/15265160903441061. No abstract available.

PMID:
20077327
11.

On the need for probity when physicians interact with industry.

Scott IA.

Intern Med J. 2006 Apr;36(4):265-9.

PMID:
16640747
12.
13.

The AAMC exhibits the behavior it condemns.

Stossel TP.

Am J Bioeth. 2010 Jan;10(1):26-7. doi: 10.1080/15265160903441095. No abstract available.

PMID:
20077333
14.

The pitfalls of misreading: what does "industry funding of medical education" actually say?

Spielman B.

Am J Bioeth. 2010 Jan;10(1):24-5. doi: 10.1080/15265160903441038. No abstract available.

PMID:
20077332
15.

Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs.

Chressanthis GA, Khedkar P, Jain N, Poddar P, Seiders MG.

J Clin Hypertens (Greenwich). 2012 Jul;14(7):435-46. doi: 10.1111/j.1751-7176.2012.00651.x. Epub 2012 May 21.

16.

[Increase in incidence of drug treatments, ethical principles and conflict of interest in cooperation with the pharmaceutical industry].

Hebebrand J, Blanz B, Herpertz-Dahlmann B, Lehmkuhl G.

Z Kinder Jugendpsychiatr Psychother. 2012 May;40(3):133-8. German. No abstract available.

PMID:
22774235
17.

Doctors behaving badly?

Tattersall MH, Kerridge IH.

Med J Aust. 2006 Sep 18;185(6):299-300. No abstract available. Erratum in: Med J Aust. 2006 Nov 20;185(10):576.

PMID:
16999666
18.
19.

Banning pens and pads misses the main point.

Terry SF, Burke W.

Am J Bioeth. 2003 Summer;3(3):63-5. No abstract available.

PMID:
14594500
20.

Getting drug money out of doctors' offices....

Nagarkar PA.

Pharos Alpha Omega Alpha Honor Med Soc. 2010 Winter;73(1):13-7. No abstract available.

PMID:
20178201

Supplemental Content

Support Center